Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| Net income | $4.046 billion (2018) |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene Corporation完全的胶质瘤 | 实体瘤 | 血管免疫母细胞性T细胞淋巴瘤 | 软骨肉瘤 | 肝内胆管癌美国, 法国
-
CelgeneCelgene Corporation完全的
-
Celgene Corporation完全的多发性骨髓瘤美国, 西班牙, 澳大利亚, 加拿大, 英国, 意大利, 瑞士, 保加利亚, 波兰, 乌克兰, 比利时, 德国, 匈牙利, 爱尔兰, 以色列, 俄罗斯联邦
-
CelgeneCelgene Corporation完全的